2021/2616(DEA)
Examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products
Basic information
2021/2616(DEA)
DEA - Delegated acts procedure
Supplementing 1999/0134(COD)
Subject
3.10.08 Animal health requirements, veterinary legislation and pharmacy
4.20.01 Medicine, diseases
4.20.04 Pharmaceutical products and industry
4.20.05 Health legislation and policy
Status
Procedure completed - delegated act enters into force
Key players
-
European Parliament
Committee responsible Rapporteur Appointed Chair on behalf of committee CANFIN Pascal (Renew)
09/03/2021
Key events
| Date | Event | Reference | Summary |
|---|---|---|---|
| 24/03/2021 | Non-legislative basic document published | C(2021)01603 | |
| 24/03/2021 | Initial period for examining delegated act 3.0 month(s) | ||
| 07/04/2021 | Delegated act not objected by Council | ||
| 27/04/2021 | Decision by Parliament | T9-0134/2021 | |
| 28/04/2021 | Committee referral announced in Parliament |
Technical information
| Procedure reference | 2021/2616(DEA) |
|---|---|
| Procedure type | DEA - Delegated acts procedure |
| Procedure subtype | Examination of delegated act |
| Supplementing 1999/0134(COD) | |
| Legal basis | Rules of Procedure EP 0114-p6 |
| Stage reached in procedure | Procedure completed - delegated act enters into force |
| Committee dossier |
ENVI/9/05567
|
Documentation gateway
-
Document type Committee Reference Date Summary Recommendation for early non-objection of delegated act B9-0226/2021 23/04/2021 Text adopted by Parliament, single reading T9-0134/2021 27/04/2021 -
Document type Reference Date Summary Non-legislative basic document C(2021)01603 24/03/2021 Document attached to the procedure C(2021)4187 08/06/2021